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Inhibition of dipeptidyl peptidase-IV (DPP-IV) is used as a means to regulate post-prandial serum glucose 
in type 2 diabetics. The effect of drug (Sitagliptin®):peptide and binary peptide mixtures on DPP-IV 
inhibition was studied using an isobole approach. Five peptides (Ile-Pro-Ile-Gln-Tyr, Trp-Lys, Trp-Pro, 
Trp-Arg and Trp-Leu), having DPP-IV half maximum inhibitory concentration values (IC50) < 60 μM and 10 
reported to act through different inhibition mechanisms, were investigated. The dose response 
relationship of Sitagliptin:peptide (1:0, 0:1, 1:852, 1:426 and 1:1704 on a molar basis) and binary Ile-Pro-
Ile-Gln-Tyr:peptide (1:0, 0:1, 1:1, 1:2 and 2:1 on a molar basis) mixtures for DPP-IV inhibition was 
characterised. Isobolographic analysis showed, in most instances, an additive effect on DPP-IV inhibition. 
However, a synergistic effect was observed with two Sitagliptin: Ile-Pro-Ile-Gln-Tyr (1:426 and 1:852) 15 
mixtures and an antagonistic effect was seen with one Sitagliptin:Trp-Pro (1:852) mixture, and three 
binary peptide mixtures (Ile-Pro-Ile-Gln-Tyr:Trp-Lys (1:1 and 2:1) and Ile-Pro-Ile-Gln-Tyr:Trp-Leu 
(1:2)). The results show that Sitagliptin and food protein-derived peptides can interact, thereby enhancing 
overall DPP-IV inhibition. Combination of Sitagliptin with food protein-derived peptides may help in 
reducing drug dosage and possible associated side-effects. 20 
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1. Introduction 
The increasing global prevalence of type 2 diabetes (T2D) has led 25 
the scientific community to investigate different strategies in 
order to slow down its evolution. Dipeptidyl peptidase IV (DPP-
IV) inhibitors belong to a new class of drugs with an antidiabetic 
action, with Sitagliptin® (Januvia®, Merck & Co., Inc. USA) 
being the first DPP-IV inhibitor launched on the market. DPP-IV 30 
cleaves incretins such as glucose dependent insulinotropic 
polypeptide (GIP) and glucagon-like peptide-1 (GLP-1) in vivo. 
Inhibition of DPP-IV therefore increases the half-life of incretins, 
thereby promoting insulin secretion from pancreatic beta cells 1. 
 Food protein-derived bioactive peptides have been shown to 35 
positively affect biomarkers of T2D such as post-prandial 
glycaemia and insulin secretion 2-4. It is thought that the 
antidiabetic properties of specific food protein hydrolysates may 
arise from their DPP-IV inhibitory activity 5,6. Food protein 
hydrolysates, originating mostly from milk, have been reported 40 
for their DPP-IV inhibitory potential 7. The peptides therein may 
inhibit DPP-IV through different modes of inhibition 8-10. In a 
physiological situation, it is expected that different food protein-
derived peptides may concomitantly inhibit DPP-IV. However, 
the contribution of multiple food protein-derived peptides, as 45 
present in food protein hydrolysates, to overall DPP-IV inhibition 
has not been determined. The combination of milk protein-
derived peptides with Sitagliptin was recently shown to have an 
additive effect on DPP-IV inhibition 11. However, to date the 
interactive effects of peptide-peptide and peptide-drug 50 
combinations on DPP-IV inhibition does not appear to have been 
extensively studied. 
 The interactive effects of drug mixtures is conventionally 
studied using an isobole methodology 12,13. It has been recently 
proposed that using combinations of antidiabetic drugs and 55 
phytochemicals may be a new approach to help reduce the side-
effects observed during drug intake 13. Synergistic antidiabetic 
activity has been shown in vivo when combinations of 
phytochemicals (ferulic acid) and antidiabetic drugs (metformin 
and thiazolidinedione) were employed 14. To our understanding, 60 
the isobole method has not been previously applied to determine 
interactive effects between drug:peptide or binary peptide 
mixtures. The aim of this study was therefore to utilise an isobole 
methodology to study the interactions between Sitagliptin and 
food protein-derived DPP-IV inhibitory peptides, and between 65 
binary mixtures of DPP-IV inhibitory peptides. 
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Table 1: Summary of the peptide cutter analysis using gastrointestinal enzyme activities to release Trp-Lys, Trp-Arg, Trp-Leu and Ile-Pro-Ile-Gln-Tyr 
from different food proteins. 
Peptide† Protein fragment Enzyme Protein source Protein 
Trp-Lys 40-41 pepsin Oat (Avena sativa) Avenin 
Trp-Arg 212-213 trypsin Wheat (Triticum aestivum) Large subunit RuBisCO* 
Trp-Arg 212-213 trypsin Barley (Hordeum vulgare) Large subunit RuBisCO 
Trp-Arg 212-213 trypsin Oat (Avena sativa) Large subunit RuBisCO 
Trp-Arg 212-213 trypsin Corn (Zea mays) Large subunit RuBisCO 
Trp-Arg 212-213 trypsin Rice (Oryza sativa subsp. Japonica) Large subunit RuBisCO 
Trp-Arg 212-213 trypsin Sorghum (Sorghum vulgare) Large subunit RuBisCO 
Trp-Arg 171-172 trypsin Quinoa (Chenopodium quinoa) RuBisCO large chain 
Trp-Arg 212-213 trypsin Amaranth (Amaranthus hypochondriacus) Large subunit RuBisCO 
Trp-Arg 207-208 trypsin Palmaria palmata (Rhodymenia palmata) Allophycocyanin α chain 
Trp-Arg 171-172 trypsin Palmaria palmata (Rhodymenia palmata) Allophycocyanin β chain 
Trp-Arg 212-213 trypsin Palmaria palmata (Rhodymenia palmata) Phycocyanin α 
Trp-Leu 104-105 elastase Bovine milk (Bos taurus) α-lactalbumin 
Ile-Pro-Ile-Gln-Tyr 26-30 chymotrypsin Bovine milk (Bos taurus) κ-casein 
†Peptide sequence using the three letter code 
*RuBisCO: Ribulose bisphosphate carboxylase 
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Fig 1: Experimental design used to study the dose response effect of (A) different Sitagliptin:peptide (Ile-Pro-Ile-Gln-Tyr, Trp-Lys, Trp-Pro, Trp-Arg and 35 
Trp-Leu) and (B) Ile-Pro-Ile-Gln-Tyr:peptide (Trp-Lys, Trp-Pro, Trp-Arg and Trp-Leu) mixtures on dipeptidyl peptidase IV (DPP-IV) inhibition. (C) 
Schematic representation of a 50% inhibition isobole diagram and interpretation of the type of interactions between two inhibitors based on the 
concentration addition (CA) value of the mixture. IC50: half maximum inhibitory concentration. 
2. Materials and methods 
2.1. Reagents 40 
Porcine DPP-IV (≥ 10 Units mg-1 protein), Gly-Pro-pNA, 
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tris(hydroxymethyl)aminomethane (TRIS), Ile-Pro-Ile and 
Sitagliptin were from Sigma Aldrich (Dublin, Ireland). Trp-Pro, 
Trp-Arg and Ile-Pro-Ile-Gln-Tyr were obtained from Thermo 
Fisher Scientific (Ulm, Germany) while Trp-Leu and Trp-Lys 
were from Bachem (Bubendorf, Switzerland). Hydrochloric acid 5 
(HCl) and high-performance liquid chromatography (HPLC) 
grade water were from VWR (Dublin, Ireland). 
2.2. In silico analysis of food proteins 
The occurrence of the five DPP-IV inhibitory peptides used in 
this study was determined in silico in 72 dietary proteins 15 10 
(Supplementary Table S1). The sequences of the mature proteins 
(without the propeptide) were obtained from UniProt using the 
ExPASy resource portal. The occurrence of the peptides was 
determined using an in-house generated Matlab programme 
(version R2014b, MathWorks, Inc, Natick, MA, USA). Proteins 15 
with the five peptides were further subjected to in silico digestion 
with gastrointestinal enzymes (pepsin, trypsin, chymotrypsin and 
elastase) using the Peptide Cutter facility in Matlab. 
 
2.3. Experimental design to study Sitagliptin-peptide and 20 
peptide-peptide interactions 
Stock solutions of peptides (900 µM) and Sitagliptin (1056 nM) 
were prepared to yield ~ 80 % DPP-IV inhibition. The ratios 
studied for the binary peptide mixtures were as described by 
Tallarida 16. The same volumetric mixtures of peptide stock 25 
solutions (i.e. 1:1, 1:2 and 2:1) were also employed for the 
Sitagliptin:peptide mixtures. For the binary peptide mixtures, 
only the combinations with the most potent substrate-type 
competitive DPP-IV inhibitor, Ile-Pro-Ile-Gln-Tyr (IC50 value of 
23 µM), and non-competitive (Trp-Lys, Trp-Pro and Trp-Arg) 30 
and competitive (Trp-Leu) DPP-IV inhibitors were studied. 
The mixtures consisted of aqueous Sitagliptin:peptide solutions 
with the following ratios of 1:0, 1:426, 1:852, 1:1704 and 0:1 on 
a molar basis. Similarly, binary mixtures of peptides consisting of 
Ile-Pro-Ile-Gln-Tyr and another peptide (Trp-Lys, Trp-Pro, Trp-35 
Arg or Trp-Leu) in the ratios of 1:0, 1:1, 2:1, 1:2 and 0:1 on a 
molar basis, were studied. The dose response for DPP-IV 
inhibition (n=3) was determined with each of the previous 
mixtures diluted in HPLC water at 7 different concentrations 
(Fig. 1 A & B). 40 
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Fig 2: Dose response curves obtained for the dipeptidyl peptidase IV (DPP-IV) inhibitory effect of (A) Sitagliptin, (B) Trp-Lys and (C), (D) and (E) 
Sitagliptin: Trp-Lys (1:852, 1:426 and 1:1704 on a molar basis) mixtures, respectively. The individual points are the mean DPP-IV inhibition  SD 
determined in triplicate (n=3).  
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Fig. 3: Dose response curves obtained for the dipeptidyl peptidase IV (DPP-IV) inhibitory effect of (A) Ile-Pro-Ile-Gln-Tyr, (B), (C) and (D) binary Ile-
Pro-Ile-Gln-Tyr:Trp-Lys (2:1, 1:1 and 1:2 on a molar basis) mixtures, respectively. The individual points are the mean DPP-IV inhibition  SD 25 
determined in triplicate (n=3). 
 
2.4. DPP-IV inhibition assay 
The DPP-IV inhibition assay was carried out essentially as 
described by Nongonierma & FitzGerald 9. Briefly, the 30 
Sitagliptin:peptide or binary peptide mixtures (25μL) were 
pipetted onto a 96 well microplate (Sarstedt, Dublin, Ireland) 
containing Gly-Pro-pNA (final concentration 0.200 mM). The 
negative control contained 100 mM Tris-HCl buffer pH 8.0 (25 
μL) and Gly-Pro-pNA. The reaction was initiated by the addition 35 
of DPP-IV (final concentration 0.0025 U mL-1). The microplate 
was incubated at 37C for 60 min in a microplate reader (Biotek 
Synergy HT, Winoosky, VT, USA) and absorbance of the 
released pNA was monitored at 405 nm. Each sample was 
analysed in triplicate (n=3). The half maximum inhibitory 40 
concentration (IC50) for DPP-IV was determined by plotting the 
percentage inhibition as a function of the concentration of test 
compounds. 
2.5. Determination of the isobole diagram at 50 % DPP-IV 
inhibition 45 
The isobole diagrams for 50 % DPP-IV inhibition were plotted 
for the different Sitagliptin:peptide or binary peptide mixtures. 
Each isobole showed the IC50 value for the inhibitors on the x and 
y axes. The line between the two IC50 values corresponds to the 
line of additivity (Fig. 1C). The concentration addition (CA) 50 
effect is described by the following equation 12: 
2,50
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 Where d1 and d2 are the concentrations of inhibitors 1 and 2, 
respectively, in a mixture yielding 50 % DPP-IV inhibition; IC50,1 
and IC50,2 are the half maximum inhibitory concentrations of 55 
inhibitors 1 and 2, respectively. 
 
 The mixture of inhibitors 1 and 2 can have an additive (CA=1), 
synergistic (CA < 1) or antagonistic effect (CA > 1) on DPP-IV 
inhibition (Fig. 1C). The theoretical total additivity concentration 60 
(Zt) of the mixture was determined as described elsewhere 17 
using an in-house Matlab program. Zt corresponds to the 
theoritical concentration of the mixture which should yield 50 % 
DPP-IV inhibition if the two inhibitors have an additive effect. Zt 
was calculated as follows: 65 
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Where p1 and p2 are the proportions of inhibitors 1 and 2, 
respectively; IC50,1 and IC50,2 are the half maximum inhibitory 
concentrations of inhibitors 1 and 2, respectively. 70 
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2.6. Statistical analysis 
Means comparison was carried out with a one way ANOVA 
followed by a Student Newman-Keuls test using SPSS (version 
22, SPSS Inc., Chicago, IL, USA) at a significance level P < 0.05. 
For each mixture, Zt was compared to the apparent IC50 value 5 
using a Student test (P < 0.05) as described elsewhere 12. 
3. Results 
3.1. Occurrence of the DPP-IV inhibitory peptides in 72 
dietary food proteins 
The five DPP-IV inhibitory peptides studied were found within 10 
50% of the dietary proteins considered (supplementary Table S1). 
The in silico digestion of the dietary proteins predicted that 4 out 
of the 5 peptides may be released from 14 of the dietary proteins 
studied. It is interesting to note that 86% of these proteins are 
plant-derived. Although Trp-Pro was present within 16 of the 15 
proteins studied, it was not predicted to be released by 
gastrointestinal enzymes (Table 1). The outcome of the in silico 
analysis suggested that 4 of the target peptides may be released 
during the digestion of foods. Therefore, they may play a role in 
DPP-IV inhibition following oral ingestion. 20 
3.2. Dose-response relationship for the Sitagliptin:peptide and 
the binary peptide mixtures 
The five DPP-IV inhibitory peptides studied were selected based 
on differences in their mode of inhibition and the fact that they 
were relatively potent food protein-derived DPP-IV inhibitors 25 
(IC50 value < 60 μM) 
8,18. The IC50 values obtained during this 
study were of the same order as previously described 8,18 
(Supplementary Table S2). Mixtures of Sitagliptin:peptides and 
binary peptides were evaluated for their ability to inhibit DPP-IV 
as outlined in section 2.4. The dose-response curves obtained for 30 
the Sitagliptin:Trp-Lys mixtures are illustrated on Fig. 2 and that 
for the binary peptide mixtures Ile-Pro-Ile-Gln-Tyr:Trp-Lys are 
shown on Fig. 3. A dose response relationship was seen with 
Sitagliptin and Ile-Pro-Ile-Gln-Tyr alone, and with all 
Sitagliptin:peptide and binary peptide mixtures (Fig. 2, 3 and data 35 
not shown). 
 
Table 2: Theoretical additivity concentration (Zt) and apparent half maximum inhibitory concentration (IC50) for the binary peptide and 
Sitagliptin:peptide mixtures. Values are mean ± confidence interval (P= 0.05) of triplicate determinations (n=3). 
   Peptide 
   Ile-Pro-Ile-Gln-Tyr Trp-Lys Trp-Pro Trp-Arg Trp-Leu 
Sitagliptin:peptide ratio (on 
a molar basis)† 
1:1704 Zt (μM) 17.3 ± 0.7 22.5 ± 3.3 22.6 ± 1.3 22.6 ± 2.0 30.4 ± 2.0 
  IC50 (μM) 18.9 ± 2.3
ns 23.5 ± 1.5 ns 22.6 ± 1.7 ns 20.5 ± 2.6 ns 28.3 ± 2.8ns 
 1:852 Zt (μM) 13.8 ± 0.7 17.1 ± 2.7 16.9 ± 1.1 16.9 ± 1.2 21.12 ± 1.9 
  IC50 (μM) 12.9 ± 0.6
* 19.6 ± 2.4 ns 18.4 ± 1.0* 16.2 ± 2.0 ns 19.1 ± 1.3ns 
 1:426 Zt (μM) 9.9 ± 0.8 11.5 ± 2.0 11.4 ± 1.0 11.4 ± 1.0 13.2 ± 1.5 
  IC50 (μM) 8.8 ± 0.5
* 13.3 ± 1.1 ns 10.1 ± 1.3ns 11.3 ± 1.8ns 11.7 ± 1.0ns 
        
Ile-Pro-Ile-Gln-Tyr:peptide 
ratio (on a molar basis)† 
1:2 Zt (μM) na 28.8 ± 2.5 29.5 ± 2.1 29.5 ± 2.5 37.9 ± 2.0 
  IC50 (μM) na 33.1 ± 5.4
ns 27.2 ± 2.5ns 26.4 ± 4.0ns 45.2 ± 6.3* 
 1:1 Zt (μM) na 27.1 ± 2.0 27.6 ± 0.4 27.6 ± 1.8 32.8 ± 1.7 
  IC50 (μM) na 36.9 ± 6.3
* 31.2 ± 3.6ns 32.2 ± 7.0 ns 36.9 ± 5.3ns 
 2:1 Zt (μM) na 25.6 ± 1.7 26.1 ± 1.5 26.0 ± 1.3 28.9 ± 1.6 
  IC50 (μM) na 31.2 ± 1.1
* 30.2 ± 6.2 ns 29.0 ± 7.1 ns 30.6 ± 2.0ns 
†Values represent the mean of triplicate determination (n=3) of the theoretical additivity concentration (Zt) ± confidence interval (P=0.05) and the 40 
apparent half maximum inhibitory concentration (IC50) ± confidence interval (P=0.05) for different Ile-Pro-Ile-Gln-Tyr:peptide (1:1, 1:2 and 2:1) and 
Sitagliptin:peptide (1:852, 1:426 and 1:1704) mixtures. 
ns: the apparent IC50 value of the mixture is not significantly different from Zt (P > 0.05) 
*: the apparent IC50 value of the mixture is significantly different from Zt (P < 0.05) 
na: not applicable 45 
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Fig 4: Isobole diagram obtained at 50 % dipeptidyl peptidase IV (DPP-IV) inhibition (IC50) for different Sitagliptin:peptide (1:0, 0:1, 1:852, 1:426 and 35 
1:1704 on a molar basis) mixtures. Each point represents the IC50 ± confidence interval (P=0.05). The peptides tested are (A) Ile-Pro-Ile-Gln-Tyr, (B) Trp-
Lys, (C) Trp-Pro, (D) Trp-Arg and (E) Trp-Leu. 
 
3.3. Sitagliptin-peptide and peptide-peptide interactions 
The 50 % isobole diagram shows the IC50 value for Sitagliptin or 40 
Ile-Pro-Ile-Gln-Tyr on the y axis and that of the peptide on the x 
axis (Fig. 4 & 5). In a few instances, the apparent IC50 value for 
the mixture was close to the line of additivity for Sitagliptin:Ile-
Pro-Ile-Gln-Tyr and Sitagliptin:Trp-Pro (1:426 and 1:852), 
Sitagliptin:Trp-Arg and Sitagliptin:Trp-Leu (1:426, 1:852 and 45 
1:1704), Ile-Pro-Ile-Gln-Tyr:Trp-Arg and Ile-Pro-Ile-Gln-
Tyr:Trp-Pro (1:2 and 2:1) and Ile-Pro-Ile-Gln-Tyr:Trp-Leu (2:1). 
For the other mixtures, the values were either in the area of the 
isobole corresponding to an antagonistic effect or in the area 
corresponding to a synergistic effect. 50 
 Most Zt values were not significantly different (P > 0.05) from 
the apparent IC50 value (Table 2), suggesting an additive effect of 
the mixture on DPP-IV inhibition. However, three 
Sitagliptin:peptide mixtures (Sitagliptin:Ile-Pro-Ile-Gln-Tyr 
(1:426 and 1:852) and Sitagliptin:Trp-Pro (1:852)) had apparent 55 
IC50 values which were significantly different (P < 0.05) from 
that of Zt (12.9 vs. 13.8, 8.8 vs. 9.9 and 18.4 vs. 16.9 μM, 
respectively), indicating a synergistic effect for the Sitagliptin:Ile-
Pro-Ile-Gln-Tyr mixtures and an antagonistic effect for the 
Sitagliptin:Trp-Pro mixture on DPP-IV inhibition. Similarly, 60 
three binary peptide mixtures (Ile-Pro-Ile-Gln-Tyr:Trp-Lys (1:1 
and 2:1) and Ile-Pro-Ile-Gln-Tyr:Trp-Leu (1:2)) had apparent 
IC50 values significantly higher than that of Zt (36.9 vs. 27.3; 
31.2 vs. 25.8 and 45.2 vs. 37.8 μM, respectively), also suggesting 
an antagonistic effect of the binary peptide mixture on DPP-IV 65 
inhibition. 
4. Discussion 
Confirmatory studies conducted with synthetic peptides, 
following mass spectrometric identification frequently show that 
several peptide sequences identified within active fractions of 70 
food protein hydrolysates display DPP-IV inhibitory properties 
5,6,10,19. This indicates that the overall DPP-IV inhibitory effect 
seen in food protein hydrolysates originates from a mixture of 
peptides rather than a single peptide. The isobole methodology 
has been mainly utilised to study interactive effects between 75 
drugs, fertilisers, pesticides and phytochemicals 13 with a limited 
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number of examples applied to antimicrobial peptide mixtures 
20,21. An additive effect of Sitagliptin (when studied at one level) 
and peptide mixtures on DPP-IV inhibitory properties has 
previously been shown 11. However, to our knowledge, study of 
the effect of drug-peptide and binary peptide mixtures on DPP-IV 5 
inhibition has not previously been described using an 
isobolographic approach. 
The synthetic substrate, Gy-Pro-pNA, used herein for the DPP-IV 
inhibitory assay has a different N-terminal amino acid sequence 
than that of the incretins (His-Ala for GLP-1 and Tyr-Ala for 10 
GIP). However, in the case of the synthetic substrate and the 
incretins, the presence of a Pro or Ala at position P1 is consistent 
with the sequence of DPP-IV preferred substrates 22,23. Therefore, 
the results described herein may be extrapolated to a 
physiological situation where food protein-derived peptides may 15 
inhibit DPP-IV, preventing incretin degradation. 
Most Sitagliptin:peptide and binary peptide mixtures showed an 
additive effect (Table 2 and Fig. 4 & 5). However, the 
Sitagliptin:Trp-Pro (1:852) mixture showed an antagonistic effect 
on DPP-IV inhibition. The extent of apparent IC50 increase 20 
compared to Zt was 9 % for the Sitagliptin:Trp-Pro (1:852) 
mixture. In the case of the Sitagliptin:Ile-Pro-Ile-Gln-Tyr (1:426 
and 1:852) mixtures, a synergistic effect was seen with a 
reduction of the IC50 value compared to Zt of 7 and 11 %, 
respectively. Although the peptides studied have different modes 25 
of inhibition (competitive, non-competitive, true or substrate-type 
inhibitor), there did not seem to be a clear trend showing specific 
types of interactions in the mixtures in one instance or the other. 
However, it is interesting to note that, the synergistic effect was 
seen with a mixture of competitive DPP-IV inhibitors (Sitagliptin 30 
and Ile-Pro-Ile-Gln-Tyr). While most antagonistic effects 
involved a non-competitive DPP-IV inhibitor (Trp-Lys and Trp-
Pro). In addition, it was not clear why the antagonistic effect was 
only seen for certain ratios of the DPP-IV inhibitors studied 
(Table 2). A number of in silico approaches have suggested that 35 
non-competitive DPP-IV inhibitors may interact at a secondary 
binding site located in the neighbourhood of the active site 24,25. 
Binding of non-competitive inhibitors to a secondary binding site 
may, in some instances, restrict access to the active site for 
competitive DPP-IV inhibitors. 40 
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Fig 5: Isobole diagram obtained at 50 % dipeptidyl peptidase IV (DPP-IV) inhibition (IC50) for binary Ile-Pro-Ile-Gln-Tyr:peptide (1:0, 0:1, 1:1, 1:2 and 
2:1) mixtures. Each point represents the IC50 ± confidence interval (P=0.05). The peptides tested were (A) Trp-Lys, (B) Trp-Pro, (C) Trp-Arg and (D) 
Trp-Leu. 75 
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Ile-Pro-Ile-Gln-Tyr behaves like a substrate type DPP-IV 
inhibitor 8. This may explain the overall increase of DPP-IV 
inhibition seen in the Sitagliptin:Ile-Pro-Ile-Gln-Tyr (1:852 and 
2:426) mixtures. Trp-Lys is an hydrophilic and positively charged 
peptide, while Ile-Pro-Ile-Gln-Tyr (pI 5.5) is negatively charged 5 
at the assay pH (8.0). It may be possible that some electrostatic 
interactions between Trp-Lys and Ile-Pro-Ile-Gln-Tyr may have 
reduced the amount of inhibitors available for DPP-IV inhibition. 
Surprisingly, no antagonistic effect was seen with Trp-Arg, which 
has very similar characteristics to Trp-Lys. An antagonistic effect 10 
was also seen in the Ile-Pro-Ile-Gln-Tyr:Trp-Leu (1:2) mixture. 
Both peptides are competitive DPP-IV inhibitors and compete for 
binding at the same site on DPP-IV. This may explain why an 
antagonistic effect was seen when Trp-Leu was present at the 
highest concentration. 15 
 The antagonistic activity of peptide mixtures on DPP-IV 
inhibition could result in the activity of specific peptides being 
“masked” by the presence of other peptides. This may have 
consequences in particular in bioassay driven fractionation 
approaches where specific fractions may be erroneously 20 
disregarded even though they contain relatively potent DPP-IV 
inhibitory peptides. Similar results have been described where the 
immunomodulatory properties of an hydrolysate was less than 
that of its associated isoelectric focusing fractions when tested at 
the same concentration 26. This was explained by the fact that 25 
some peptides may interact through physicochemical interactions 
27, making them unavailable as bioactive components. 
 A well-known example of a food drug interaction is the 
combination of grapefruit juice and drugs. Furanocoumarin from 
grapefruit juice has been shown to inhibit the drug metabolising 30 
enzyme, cytochrome P450 (CYP) 34A 28. In terms of antidiabetic 
activity, small animal studies have demonstrated that the 
ingestion of Leu-Pro-Gln-Asn-Ile-Pro-Pro-Leu (β-casein f70-77, 
DPP-IV IC50 = 160 μM) or a tryptic β-lactoglobulin hydrolysate 
containing Val-Ala-Gly-Thr-Trp-Tyr (β-lg f15-20, DPP-IV IC50 = 35 
174 μM) could lower plasma glucose following an oral glucose 
tolerance test 5,6. Recently, it was shown that a porcine skin 
gelatin hydrolysate could inhibit plasma DPP-IV in rats as well as 
reducing serum glucose in the post-prandial phase 29. However, 
little or no data appears to exist on the effect of foods on the 40 
pharmacokinetics of Sitagliptin in vivo following food intake 30. 
There is therefore a need to evaluate the peptide sequences 
studied herein in humans to assess their in vivo biological 
activity. The interactions reported with the Sitaglitpin:peptide 
mixtures suggest that it may be possible to lower drug intake 45 
level when combined with food protein-derived DPP-IV 
inhibitory peptides. This may help to reduce the possible side-
effects associated with drug intake 31. 
Conclusion 
A systematic approach has been utilised to study the effect of 50 
Sitagliptin:peptide and binary peptide mixtures on DPP-IV 
inhibition using an isobole methodology. It was shown in most 
cases that there was an additive effect of the mixtures on overall 
DPP-IV inhibition. However, in some instances antagonistic or 
synergistic effects were observed. Since the ability of food 55 
protein-derived peptides to inhibit DPP-IV has been 
demonstrated in vitro, the interactive effects described herein 
may therefore be relevant to the post-prandial regulation of serum 
glucose and to the pharmacokinetics of antidiabetic drugs. In 
addition, the isobolographic approach used herein may aid in the 60 
formulation of foods with a desired DPP-IV inhibitory profile 
which in turn may complement the effects of T2D preventative 
and therapeutic agents. In vivo studies are required to test these 
hypotheses. 
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Supplementary data 
 
Table S1: In silico analysis showing the occurrence of Trp-Lys, Trp-Pro, Trp-Arg, Trp-Leu and Ile-Pro-Ile-Gln-Tyr in food proteins. 
   Peptide occurrence in proteins‡ 
Origin Protein
* 
Accession 
number† Ile-Pro-Ile-Gln-Tyr Trp-Arg Trp-Lys Trp-Leu Trp-Pro 
Wheat (Triticum aestivum) α/ β-gliadin P02863 0 0 0 0 0 
 
Glutenin, high molecular 
weight subunit 12 
P08488 
0 0 0 0 0 
 
Glutenin, low molecular 
weight subunit 1D1 
P10386 
0 0 0 0 0 
 Large subunit RuBisCO P11383 0 1 1 0 0 
 Small subunit RuBisCO P26667 0 0 1 0 1 
Barley (Hordeum vulgare) B hordein Q40026 0 0 0 0 1 
 
D hordein Q40054 0 0 0 0 0 
 γ-hordein-3 P80198 0 0 0 0 0 
 Large subunit RuBisCO P05698 0 1 1 0 0 
 Small subunit RuBisCO Q40004 0 0 1 0 1 
Oat (Avena sativa) Avenin P27919 0 1 2 0 1 
 11S globulin Q38779 0 0 0 0 0 
 12S globulin Q49257 0 0 0 0 1 
 Large subunit RuBisCO P48684 0 1 1 0 0 
 Small subunit RuBisCO Q9ZWG4 0 0 1 0 1 
Corn (Zea mays) Large subunit RuBisCO P00874 0 1 1 0 0 
 
Small subunit RuBisCO P05348 0 0 1 0 1 
Rice (Oryza sativa subsp. 
Japonica) 
Large subunit RuBisCO P0C512 
0 1 1 0 0 
 
Small subunit RuBisCO P18566 0 0 1 0 1 
Sorghum (Sorghum 
vulgare) 
Large subunit RuBisCO A1E9T2 
0 1 1 0 0 
 
Small subunit RuBisCO C5Y519 0 0 1 0 1 
Soybean (Glycine hispida) Basic 7S P13917 0 1 0 0 0 
 Glycinin P04347 0 0 0 0 0 
 β-conglycinin, β-chain P25974 0 0 0 0 0 
 β-conglycinin, α-chain P13916 0 0 0 0 1 
 β-conglycinin, α’-chain P11827 0 0 0 0 0 
Quinoa (Chenopodium 
quinoa) 
RuBisCO large chain K4P448 
0 1 0 0 0 
Canola (Brassica napus) Cruciferin P11090 0 0 0 0 0 
 Napin small chain P17333 0 0 0 1 0 
 Napin large chain P17333 0 0 0 0 0 
Amaranth (Amaranthus 
hypochondriacus) 
Large subunit RuBisCO P16306 
0 1 1 0 0 
Palmaria palmata 
(Rhodymenia palmata) 
50S ribosomal protein L31, 
chloroplastic 
Q5MIM5 
0 0 0 0 0 
 
PALPL Ribosomal protein 
12 
Q5MIL8 
0 0 0 0 0 
 Allophycocyanin α chain M1UZ22 0 1 1 0 0 
 Allophycocyanin β chain M1VJV1 0 1 0 0 0 
 Phycocyanin α I2FJU0 0 1 1 0 0 
 Phycocyanin β I2FJT9 0 0 1 0 1 
 Phycoerythrin α subunit F2ZAL8 0 0 0 0 0 
 Phycoerythrin β subunit F2ZAL7 0 0 0 0 0 
 RuBisCO large chain  Q9THF8 0 0 0 0 0 
 RuBisCO small chain O98734 0 0 0 0 0 
 Small subunit RuBisCO Q9XGX5 0 0 1 0 1 
Chicken egg (Gallus gallus) Ovalbumin P01012 0 0 0 0 0 
 Ovotransferrin P02789 0 0 0 0 0 
 Ovomucoid P01005 0 0 0 0 0 
Bovine milk (Bos taurus) αs1-casein P02662 0 0 0 0 0 
 αs2-casein P02663 0 0 0 0 0 
 β-casein P02666 0 0 0 0 0 
 κ-casein P02668 1 0 0 0 0 
 β-lactoglobulin P02754 0 0 0 0 0 
 α-lactalbumin P00711 0 0 0 2 0 
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 Lactoferrin P24627 0 1 1 0 0 
 BSA P02769 0 0 0 0 0 
Bovine meat (Bos taurus) Myosin-1 Q9BE40 0 1 1 2 1 
 
Myosin regulatory light 
chain 12B 
A4IF97 
0 0 0 0 0 
 Actin, cytoplasmin 1 P60712 0 0 0 0 0 
 Collagen α-1 (III) chain P02459 0 0 1 0 0 
Pig (Sus scrofa) β-actin  Q8SPK6 0 0 0 0 0 
 Actin, α skeletal muscle P68137 0 0 0 0 0 
 Myosin light chain Q29069 0 0 0 0 0 
 Myosin heavy chain Q29623 0 0 0 1 0 
Atlantic salmon (Salmo 
salar) 
Actin, cytoplasmic 1 O42161 
0 0 0 0 0 
 
Myosin regulatory light 
chain 2 
Q7ZZN0 
0 0 0 0 0 
 Slow myosin heavy chain Q2HXU3 0 0 0 1 0 
 Collagen Type XI α2 A7KE05 0 1 0 0 0 
Chum salmon 
(Oncorhynchus keta) 
Type 1 collagen α2 chain Q8UUJ4 
0 0 0 0 0 
 Actin Q9PVN1 0 0 0 0 0 
 β-actin J7ID80 0 0 0 0 0 
 Myosin heavy chain Q8JIP5 0 2 1 2 1 
Tuna (Thunnus orientalis) β-actin A9CM08 0 0 0 0 0 
 Myosin heavy chain-1 G9M5T1 0 1 1 2 1 
 Myosin heavy chain-2 G9M5T2 0 1 1 2 1 
*
RuBisCO: Ribulose bisphosphate carboxylase; BSA bovine serum albumin 
†Accession number from UniProt database, data presented within this table is relative to the mature protein sequence 
‡0: peptide not found within the protein sequence; 1 and 2: peptide found once or twice, respectively, within the protein sequence 
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Table S2: Inhibitory concentration inducing 50 % inhibition (IC50) for dipeptidyl peptidase IV (DPP-IV) and type of inhibition as determined by 
Lineweaver and Burk analysis.  
Compound IC50 (μM)
* Type of inhibition‡ 
Sitagliptin 0.037 ± 0.009a competitive 
Ile-Pro-Ile 3.6 ± 0.6b substrate-type, competitive 
Ile-Pro-Ile-Gln-Tyr 23.3 ± 1.4c substrate-type, competitive 
Trp-Lys 33.1 ± 4.0d non-competitive 
Trp-Pro 33.3 ± 2.8d non-competitive 
Trp-Arg 34.9 ± 6.0d non-competitive 
Trp-Leu 53.9 ± 2.4e true, competitive 
*
Values represent the mean half maximum inhibitory concentration (IC50) ± confidence interval (P=0.05). Values with different superscript letters are 
significantly different (P <0.05) 5 
‡Type of DPP-IV inhibition as reported elsewhere 18,32 
 
 
